

SIL1 RABBIT PAB

货号: S219473

产品全名: SIL1 兔多抗

基因符号: BAP; MSS; ULG5

UNIPROT ID: Q9H173 (Gene Accession - BC011568)

背景: This gene encodes a resident endoplasmic reticulum (ER), N-linked glycoprotein with an N-terminal ER targeting sequence, 2 putative N-glycosylation sites, and a C-terminal ER retention signal. This protein functions as a nucleotide exchange factor for another unfolded protein response protein. Mutations in this gene have been associated with Marinesco-Sjogren syndrome. Alternate transcriptional splice variants have been characterized.

抗原: Fusion protein of human SIL1

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 150-300;WB: 500-2000;ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 219473(SIL1 Antibody) at a dilution of 1/130(Cytoplasm).




In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 219473(Anti-SIL1 Antibody) at dilution 1/130.



The image on the left is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using 219473(Anti-SIL1 Antibody) at a dilution of 1/130.



In comparison with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with fusion protein and then with D227290(Anti-SIL1 Antibody) at dilution 1/130.



Gel: 8%SDS-PAGE, Lysate: 40 µg;
Lane 1-3: HeLa, K562 and HepG2 cell lysates;
Primary antibody: 219473(SIL1 Antibody) at dilution 1/400;
Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution;
Exposure time: 10 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
